AU2018329202B2 - Methods for making and using endoxifen - Google Patents

Methods for making and using endoxifen Download PDF

Info

Publication number
AU2018329202B2
AU2018329202B2 AU2018329202A AU2018329202A AU2018329202B2 AU 2018329202 B2 AU2018329202 B2 AU 2018329202B2 AU 2018329202 A AU2018329202 A AU 2018329202A AU 2018329202 A AU2018329202 A AU 2018329202A AU 2018329202 B2 AU2018329202 B2 AU 2018329202B2
Authority
AU
Australia
Prior art keywords
endoxifen
composition
subject
formula
hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018329202A
Other languages
English (en)
Other versions
AU2018329202A1 (en
Inventor
ChuanDer HUANG
Steven C. Quay
YaoLin SUN
Lunghu Wang
ChangJung WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atossa Therapeutics Inc
Original Assignee
Atossa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65635248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018329202(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atossa Therapeutics Inc filed Critical Atossa Therapeutics Inc
Publication of AU2018329202A1 publication Critical patent/AU2018329202A1/en
Application granted granted Critical
Publication of AU2018329202B2 publication Critical patent/AU2018329202B2/en
Priority to AU2023200013A priority Critical patent/AU2023200013B2/en
Priority to AU2024278243A priority patent/AU2024278243A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Catalysts (AREA)
  • Dental Preparations (AREA)
  • Primary Cells (AREA)
  • Paper (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2018329202A 2017-09-11 2018-09-10 Methods for making and using endoxifen Active AU2018329202B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023200013A AU2023200013B2 (en) 2017-09-11 2023-01-03 Methods for making and using endoxifen
AU2024278243A AU2024278243A1 (en) 2017-09-11 2024-12-10 Methods for making and using endoxifen

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762556799P 2017-09-11 2017-09-11
US201762556884P 2017-09-11 2017-09-11
US62/556,799 2017-09-11
US62/556,884 2017-09-11
US201862624787P 2018-01-31 2018-01-31
US62/624,787 2018-01-31
US201862693885P 2018-07-03 2018-07-03
US62/693,885 2018-07-03
PCT/US2018/050272 WO2019051416A1 (en) 2017-09-11 2018-09-10 METHODS FOR THE MANUFACTURE AND USE OF ENDOXIFEN

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023200013A Division AU2023200013B2 (en) 2017-09-11 2023-01-03 Methods for making and using endoxifen

Publications (2)

Publication Number Publication Date
AU2018329202A1 AU2018329202A1 (en) 2020-03-19
AU2018329202B2 true AU2018329202B2 (en) 2022-10-27

Family

ID=65635248

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018329202A Active AU2018329202B2 (en) 2017-09-11 2018-09-10 Methods for making and using endoxifen
AU2023200013A Active AU2023200013B2 (en) 2017-09-11 2023-01-03 Methods for making and using endoxifen
AU2024278243A Pending AU2024278243A1 (en) 2017-09-11 2024-12-10 Methods for making and using endoxifen

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023200013A Active AU2023200013B2 (en) 2017-09-11 2023-01-03 Methods for making and using endoxifen
AU2024278243A Pending AU2024278243A1 (en) 2017-09-11 2024-12-10 Methods for making and using endoxifen

Country Status (12)

Country Link
US (8) US11261151B2 (enExample)
EP (1) EP3681491A4 (enExample)
JP (3) JP7766316B2 (enExample)
KR (2) KR20200052349A (enExample)
CN (2) CN111328280A (enExample)
AU (3) AU2018329202B2 (enExample)
CA (1) CA3073836A1 (enExample)
IL (3) IL272924B2 (enExample)
MX (1) MX2020002649A (enExample)
SG (1) SG11202002105WA (enExample)
TW (2) TWI793165B (enExample)
WO (1) WO2019051416A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. Methods for making and using endoxifen
JP7662204B2 (ja) * 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物
CN110564962B (zh) * 2019-10-14 2020-12-22 中南大学 一种黑白钨混合矿的冶炼方法
CN113975279A (zh) * 2021-10-13 2022-01-28 复旦大学附属肿瘤医院 维拉佐酮及其衍生物在制备抗肿瘤药物中的应用
MX2024008643A (es) * 2022-01-12 2024-09-25 Atossa Therapeutics Inc Composiciones de (z)-endoxifeno y métodos de enriquecimiento de este.
IL316562A (en) * 2022-04-26 2024-12-01 Atossa Therapeutics Inc High-dose and convenient formulations of endoxifen
TW202510843A (zh) * 2023-07-19 2025-03-16 美商阿托薩醫療公司 因多昔芬（ｅｎｄｏｘｉｆｅｎ）組合物及其使用方法及其合成
WO2025137145A1 (en) 2023-12-18 2025-06-26 Atossa Therapeutics, Inc. Oral formulations of (z)-endoxifen and methods of use thereof
WO2025151443A1 (en) 2024-01-08 2025-07-17 Atossa Therapeutics, Inc. Endoxifen for treatment of rare cancers
WO2025207636A1 (en) 2024-03-25 2025-10-02 Atossa Therapeutics, Inc. Endoxifen for treating duchenne muscular dystrophy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070651A1 (en) * 2015-10-22 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Process for preparing (z)-endoxifen of high purity

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
GB2160202B (en) 1984-06-12 1987-12-02 Nat Res Dev Preparation of tamoxifen
GB8604528D0 (en) 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
US6881548B2 (en) 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US6638727B1 (en) 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6398765B1 (en) 1999-03-01 2002-06-04 Pro Duct Health, Inc. Apparatus, methods and kits for simultaneous delivery of a substance to multiple breast milk ducts
US6245352B1 (en) 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Therapy
US6416981B1 (en) 2000-05-23 2002-07-09 Nec Partnership Production of gluconate salts
IL161491A0 (en) 2001-11-07 2004-09-27 Synthon Bv Tamsulosin tablets
WO2004087123A1 (en) 2003-04-01 2004-10-14 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
MXPA05006526A (es) 2002-12-18 2006-02-17 Besins Int Lab Tratamiento de mastalgia con 4-hidroxi tamoxifen.
EP2050443B1 (en) 2002-12-18 2017-05-24 Besins Healthcare Luxembourg SARL Reduction of breast density with 4-hydroxy tamoxifen
NZ544851A (en) 2003-06-23 2008-03-28 Macrochem Corp A vanishing cream base composition suitable for topical administration of an active agent to an animal or plant
US7531578B2 (en) 2003-09-18 2009-05-12 City Of Hope Compounds and methods for treating breast cancer and other diseases
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
ATE548375T1 (de) 2004-01-16 2012-03-15 Cedarburg Pharmaceuticals Inc Exemestan und zwischenprodukte davon und verfahren zu dessen herstellung
US8436029B2 (en) 2004-03-19 2013-05-07 Transform Pharmaceuticals, Inc. Pharmaceutical forms, and methods of making and using the same
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20070059288A1 (en) 2005-03-31 2007-03-15 Dinsmore Jonathan H Treatment for heart disease
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
JP2008516005A (ja) 2005-07-06 2008-05-15 シコール インコーポレイティド レトロゾールの改良された調製方法
US20080319092A1 (en) 2005-08-05 2008-12-25 Nuvo Research Inc. Transdermal Drug Delivery Formulation
RU2008118363A (ru) 2005-10-12 2009-11-20 Кова Ко., Лтд. (Jp) Ионтофоретический препарат для лечения рака молочной железы и/или мастита
US20090208944A1 (en) 2005-12-09 2009-08-20 Goetz Matthew P Assessing outcomes for breast cancer patients treated with tamoxifen
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
US9308181B2 (en) 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
WO2007141799A1 (en) 2006-06-05 2007-12-13 Cadila Healthcare Limited A process for preparing pure anastrozole
CA2665105A1 (en) 2006-10-05 2008-04-10 Panacea Biotec Ltd. Injectable depot composition and its' process of preparation
US20120164075A1 (en) * 2006-11-21 2012-06-28 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of mammalian diseases
IN2014MN00139A (enExample) 2006-11-21 2015-06-19 Jina Pharmaceuticals Inc
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
US20080207644A1 (en) 2006-11-27 2008-08-28 Sonis Stephen T Therapeutic materials and methods
WO2008067991A2 (en) 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
WO2008113177A1 (en) 2007-03-20 2008-09-25 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
CA2680825C (en) 2007-03-22 2013-10-29 Cytotech Labs, Llc Topical formulations having enhanced bioavailability
WO2009032699A1 (en) 2007-08-29 2009-03-12 Drugtech Corporation Anti-proliferative combinations
AR068409A1 (es) 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
EP2212301B1 (en) 2007-11-28 2012-02-29 Fresenius Kabi Oncology Limited An improved process for preparation of letrozole and its intermediates
WO2009120999A2 (en) 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
WO2009129352A2 (en) 2008-04-15 2009-10-22 Windy Hill Medical Device and method for accessing and treating ducts of mammary glands
US8063249B1 (en) 2008-04-25 2011-11-22 Olema Pharmaceuticals, Inc. Substituted triphenyl butenes
NZ590268A (en) 2008-07-08 2012-11-30 Incyte Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
WO2010009335A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
WO2010043404A1 (en) 2008-10-15 2010-04-22 Synthon B.V. Processes and intermediates for the production of fulvestrant
US20100098659A1 (en) 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
ES2624557T3 (es) 2008-12-11 2017-07-14 Besins Healthcare Luxembourg Sarl Composiciones farmacéuticas transdérmicas que comprenden un SERM
CN101891635B (zh) * 2009-05-21 2014-06-04 扬子江药业集团有限公司 枸橼酸他莫昔芬的晶型及晶型a的制备方法
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
WO2011031561A2 (en) 2009-08-27 2011-03-17 Ensisheim Partners Llc Nucleic acid molecules and uses thereof
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
WO2011072244A1 (en) 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
EP2425833A1 (de) 2010-09-03 2012-03-07 Fresenius Kabi Deutschland GmbH Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
KR101308258B1 (ko) 2010-10-15 2013-09-13 씨제이제일제당 (주) 엔독시펜의 신규한 제조 방법
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9200045B2 (en) 2011-03-11 2015-12-01 President And Fellows Of Harvard College Small molecule-dependent inteins and uses thereof
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
WO2012162492A1 (en) 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Compressed core comprising organic acids for a pharmaceutical composition
US9090640B2 (en) 2011-09-02 2015-07-28 Ulrich Bierbach Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
FR2980972B1 (fr) 2011-10-05 2014-02-28 Commissariat Energie Atomique Formulations pour le diagnostic et le traitement de cancers hormonodependants et de cancers des organes de synthese d'hormones steroidiennes.
US9353132B2 (en) 2012-03-05 2016-05-31 Xavier University Of Louisiana Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
US9220680B2 (en) 2012-07-13 2015-12-29 South Dakota State University Compositions and methods for localized drug delivery through mammary papillae
US20150321983A1 (en) 2012-10-19 2015-11-12 Fermion Oy A process for the preparation of ospemifene
KR20150087400A (ko) 2012-11-20 2015-07-29 버텍스 파마슈티칼스 인코포레이티드 인돌아민 2,3-디옥시게나제의 억제제로서 유용한 화합물
PL2961831T3 (pl) 2013-02-26 2020-12-14 Memorial Sloan Kettering Cancer Center Kompozycje i sposoby do immunoterapii
IN2013MU00646A (enExample) 2013-03-04 2015-06-26 Intas Pharmaceuticals Ltd
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
TW201536278A (zh) * 2013-05-31 2015-10-01 Del Mar Pharmaceuticals 雙脫水半乳糖醇及其類似物與衍生物用於治療復發性惡性神經膠瘤或進行性繼發腦瘤之用途
CA2927752A1 (en) 2013-10-18 2015-04-23 The Regents Of The University Of Michigan Systems and methods for determining a treatment course of action
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015106094A1 (en) 2014-01-10 2015-07-16 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
CN106068121A (zh) 2014-03-11 2016-11-02 利普生物药剂公司 使用单一溶剂进行克罗米芬合成
JP6757935B2 (ja) 2014-06-04 2020-09-23 アトッサ ジェネティックス インク． 分子マンモグラフィ
CN104230723B (zh) 2014-08-21 2016-08-24 凯莱英医药集团（天津）股份有限公司 托瑞米芬的合成方法
JP2018514511A (ja) 2015-04-14 2018-06-07 アトッサ ジェネティックス インク． 乳房障害とエストロゲン関連障害の処置のための組成物と方法
US10314854B2 (en) 2015-05-15 2019-06-11 University Of Iowa Foundation Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
JP2018520182A (ja) 2015-07-14 2018-07-26 アトッサ ジェネティックス インク． 乳房障害を処置するための経乳頭方法及び組成物
DE102015222031A1 (de) * 2015-11-10 2017-05-11 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Synthese von (Z)-Endoxifenhydrochlorid
US20170304232A1 (en) 2016-04-20 2017-10-26 Northwestern University Endoxifen For Local Transdermal Therapy To The Breast
MX2020002683A (es) 2017-09-11 2020-09-25 Atossa Therapeutics Inc Composiciones topicas y metodos de tratamiento.
KR20200051690A (ko) 2017-09-11 2020-05-13 아토사 테라퓨틱스, 인크. 국소 조성물
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. Methods for making and using endoxifen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070651A1 (en) * 2015-10-22 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Process for preparing (z)-endoxifen of high purity

Also Published As

Publication number Publication date
US11261151B2 (en) 2022-03-01
CN116832020A (zh) 2023-10-03
IL272924A (en) 2020-04-30
US20200207704A1 (en) 2020-07-02
TW201919596A (zh) 2019-06-01
KR20200052349A (ko) 2020-05-14
US20230183166A1 (en) 2023-06-15
AU2024278243A1 (en) 2025-01-02
IL304863B1 (en) 2025-04-01
JP2023126540A (ja) 2023-09-07
CN111328280A (zh) 2020-06-23
US20240327333A1 (en) 2024-10-03
IL272924B2 (en) 2024-01-01
MX2020002649A (es) 2020-09-25
SG11202002105WA (en) 2020-04-29
US20220242816A1 (en) 2022-08-04
US20240425443A1 (en) 2024-12-26
US12479790B2 (en) 2025-11-25
AU2023200013B2 (en) 2024-09-12
IL319158A (en) 2025-04-01
JP7766316B2 (ja) 2025-11-10
US11572334B2 (en) 2023-02-07
AU2023200013A1 (en) 2023-02-09
TWI878810B (zh) 2025-04-01
US20230365490A1 (en) 2023-11-16
US20250223256A1 (en) 2025-07-10
US12275684B2 (en) 2025-04-15
US12281056B2 (en) 2025-04-22
TWI793165B (zh) 2023-02-21
US20250282710A1 (en) 2025-09-11
EP3681491A4 (en) 2021-06-30
JP2020533283A (ja) 2020-11-19
KR20240155974A (ko) 2024-10-29
IL304863A (en) 2023-10-01
JP2025061858A (ja) 2025-04-11
IL304863B2 (en) 2025-08-01
TW202428251A (zh) 2024-07-16
US11680036B1 (en) 2023-06-20
CA3073836A1 (en) 2019-03-14
US12071391B2 (en) 2024-08-27
AU2018329202A1 (en) 2020-03-19
EP3681491A1 (en) 2020-07-22
WO2019051416A1 (en) 2019-03-14
IL272924B1 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
US12479790B2 (en) Methods for making and using endoxifen
JP2023126540A5 (enExample)
US20250066286A1 (en) Compositions of (z)-endoxifen and methods of enrichment thereof
KR20240093500A (ko) 암 치료를 위한 엔독시펜
HK40031003A (en) Methods for making and using endoxifen
TW202510843A (zh) 因多昔芬（ｅｎｄｏｘｉｆｅｎ）組合物及其使用方法及其合成
CN118647598A (zh) (z)-因多昔芬的组合物和其富集方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)